Downloadable Slidesets

Share

Program Content

Activities

  • PARPi Monotherapy in PCa
    Single-Agent PARP Inhibitors in Prostate Cancer
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: January 24, 2024

  • Rationale for PARP Combos in PCa
    Leveraging Interdependencies of Targeted Pathways: Rationale for PARPi Combinations
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: January 24, 2024

  • PARPi Combinations in PCa
    PARP Inhibitor/AR Pathway Inhibitor Combination Approaches in Prostate Cancer
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: January 24, 2024

Faculty

cover img faculity

Neeraj Agarwal, MD

Professor of Medicine
Senior Director for Clinical Research, Huntsman Cancer Institute (HCI)
Presidential Endowed Chair of Cancer Research
Director, Center of Investigational Therapeutics
Director, Genitourinary Oncology Program
Huntsman Cancer Institute, University of Utah (NCI-CCC)
Salt Lake City, Utah

cover img faculity

Andrew Armstrong, MD, ScM, FACP

Professor of Medicine, Surgery, Pharmacology and Cancer Biology
Director of Research
The Duke Cancer Institute Center for Prostate and Urologic Cancers
Divisions of Medical Oncology and Urology
Duke University
Durham, North Carolina

cover img faculity

Tanya B. Dorff, MD

Professor of Medicine
Vice Chair for Clinical Affairs
Department of Medical Oncology
City of Hope National Medical Center
Duarte, California

Provided by

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Merck & Co., Inc., Rahway, NJ, USA.

AstraZeneca

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Merck & Co., Inc., Rahway, NJ, USA